Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2Phase 2 2Phase 1/2 2Phase NA 1Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroblastoma 3Pheochromocytoma 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Ganglioneuroblastoma 1Disease 1

Interventions

Everolimus 6lutetium Lu 177 dotatate 5lanreotide 4Octreotide 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4amino-acid, glucose, and electrolyte solution 3Capecitabine 3surufatinib 2fluorodopa F 18 2Introns 2telotristat ethyl 1copper dotatate CU-64 1cabozantinib 1X-Rays 1Temozolomide 1Sunitinib 1Specimen Handling 1Somatostatin 1Serotonin 1Salts 1Phantoms, Imaging 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Lutetium-177 1Lutetium 1Leucovorin 1Interferon alpha-2 1Immunoglobulin G 1Ga(III)-DOTATOC 1Furosemide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neuroendocrine Tumors × 3-Iodobenzylguanidine × Clear all
NCT00037869 2018-10-31

High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors

M.D. Anderson Cancer Center

Phase 3 Completed
15 enrolled
EndocrineNET

Neoplasm Metastasis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡